Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada
Milan, Italy and Montreal, Quebec – July 10, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to report that its partner Zambon S.p.A. and Valeo Pharma Inc. announced today the launch of Onstryv® (safinamide) for the treatment of Parkinson’s disease in Canada.
“This marks another key milestone for Newron and its commercial partners in providing availability of safinamide in Canada for the treatment of patients suffering from Parkinson’s disease,” commented Newron CEO Stefan Weber. “Now, with the Canadian launch, safinamide is available across the North American region.”
The full text of the announcement from Zambon S.p.A and Valeo Pharma Inc. is as follows:
Valeo Pharma Announces the Canadian Launch of Onstryvâ (Safinamide Tablets) for the Treatment of Parkinson’s Disease
· First new oral treatment for Parkinson’s Disease approved in over a decade
· Parkinson’s Disease affects a growing number of Canadians with over 100,000 currently afflicted
· Total Canadian market for Parkinson’s Disease drugs exceeds $100 million per year
MONTREAL, QUEBEC, July 10, 2019 – Valeo Pharma Inc. (CSE:VPH) (“Valeo”), a Canadian specialty pharmaceutical company with a primary focus on Neurodegenerative Diseases and Oncology, today announced the launch of Onstryv® (safinamide tablets) for the treatment of patients suffering from Parkinson’s Disease in Canada. Valeo has the exclusive rights to commercialize Onstryv® in Canada under a license agreement signed with Zambon S.p.A.
Valeo announced the approval of Onstryv® by Health Canada, on January 15, 2019, as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease in patients experiencing “off” episodes.
Onstryvâ is a prescription medication now available at pharmacies across Canada and comes in 50mg and 100mg tablets. Valeo’s national sales team has launched a physician awareness and information campaign which is being supported by marketing and social media activities.
“The number of Canadians afflicted with Parkinson’s Disease is expected to grow by more than 50% over the next decade as the Canadian population ages,” said Steve Saviuk, Chief Executive Officer of Valeo. “Onstryv® is the first new oral treatment for Parkinson’s Disease to be approved in Canada in well over a decade. Many patients experience progressive symptom difficulties with currently available treatments, and we are proud to bring a new option to address this growing need for Canadian patients. Valeo is committed to building and supporting relationships with healthcare professionals, patients and other stakeholders to build awareness and ensure access to this new treatment for Parkinson’s Disease.”
Roberto Tascione, CEO of Zambon said: “Since 1906, Zambon is committed to provide innovative medicines for patients and doctors and this launch is another significant step forward to fulfill our vision: Innovating Cure & Care to make patients’ lives better. Right now, with this important milestone, Safinamide has been launched in 14 European Union countries, Switzerland, U.S.A., Australia and Canada and has recently been approved in Brazil and Colombia.”
Parkinson’s Disease is a progressive neurological disease involving the loss of dopamine-producing neurons in the brain. While tremors are the best-known symptom, Parkinson’s Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the highest incidences of Parkinson’s Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases.
About Onstryv® (safinamide)
Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a new chemical entity with a unique mode of action including selective and reversible MAO-B-inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24-month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor
fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity. Zambon acquired rights from Newron Pharmaceuticals (www.newron.com) to develop and commercialize Xadago® globally, excluding Japan and other key Asian territories where Meiji Seika Pharma has the rights to develop and commercialize safinamide. The rights to commercialize Xadago® in the USA have been granted to US WorldMeds, by Zambon.
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on Neurodegenerative Diseases, Oncology, Women’s Health and Hospital Specialty Products, Valeo Pharma has a growing portfolio of innovative products and the full infrastructure to properly manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com.
About Zambon
Zambon is a multinational pharmaceutical and fine-chemical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives. Based on a valuable heritage but strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality medicines. Zambon products are commercialized in 86 countries. The company has 20 subsidiaries in three different Continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, France, China and Brazil. The company today has a strong focus on the treatment of rare diseases such as Cystic Fibrosis and specialties, such as Parkinson’s disease, and it’s well-established in 3 therapeutic areas: respiratory, pain and women’s care. Zambon was established in 1906 in Italy and today counts around 2,700 employees all over the world. For details on Zambon please visit www.zambon.com.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
New Committee Brings Diverse Patient, Family, and Caregiver Voices to CADTH
OTTAWA, July 10, 2019 /CNW/ - Following a nationwide call for nominations, CADTH is pleased to announce the membership of its new Patient and Community Advisory Committee.
Twelve individuals from across the country have been invited to join the committee as inaugural members. Committee members are patients or family caregivers and reflect the diversity of people and communities across Canada. Members will advise CADTH on all areas of the agency's work from the perspective of individuals using the Canadian health care system.
"This important committee ensures that CADTH is even more inclusive, transparent, and accountable to patients, families, and caregivers," said Dr. Brian O'Rourke, President and CEO of CADTH. "Working closely with patients and communities helps us better serve the health care decision-makers who rely on CADTH to make equitable choices about the appropriate use of health technologies."
The committee will meet four times a year and report to the President and CEO of CADTH.
The members of the CADTH Patient and Community Advisory Committee are:
Marilyn Barrett, the Director of the Health & Wellness Centre at the University of Prince Edward Island. She is a retired community nurse and the former Director of Primary Care for Health for Health PEI. Marilyn has been a caregiver to multiple family members, which required out-of-province care for health treatment.
Jonah Dupuis, a community pharmacist in Northwestern Ontario, who has previously served as a councillor on Nipigon's Town Council and the director of pharmacy at the Nipigon District Memorial Hospital. Jonah is a proud member of the Anishinabek Nation and currently works in a travelling health team that delivers primary health care directly to First Nations communities. He also is a caregiver for his son who lives with a rare genetic condition.
Lilian Hulme-Smith, a retired public servant, who spent the bulk of her career in social and supportive housing administration and risk management. She is a member of the Mackenzie Health Mackenzie Richmond Hill Hospital Patient Advisory Committee and Medication Safety Committee, as well as a patient advisor at the Central Local Health Integration Network. Lilian lives with primary-progressive multiple sclerosis.
Beth Kidd, the Executive Director of Health Coalition of Alberta, representing more than 90 health charities, as well as individuals, that advocate for improved access to care and greater patient engagement. Beth lives with chronic migraines and is a Board member of Migraine Canada and Dementia Network Calgary.
Marlee McGuire, a medical anthropologist and a doctoral student at the University of British Columbia, where her research focuses on the politics of rare diseases though multi-stakeholder perspectives, including patient and public payer perspectives. Marlee has navigated systems around addiction and chronic conditions as a family member.
David McMullen, a retired engineer and manager with Ontario Power Generation. David has been a multiple myeloma patient since 2012. He is very active with Myeloma Canada, contributing to its objectives of patient and caregiver education and support, research, access to treatments, and awareness. David was the founding Chair of the Myeloma Canada Patient Advisory Council. He has leadership and advisory roles in several myeloma patient support groups. He is also a patient representative in the Canadian Cancer Trials Group.
Devan Nambiar,MSc., an education and training specialist on LGBT2SQ+ health and HIV care for organizations, clinicians, and allied health professionals through Rainbow Health Ontario, Sherbourne Health, with his own consultancy, GHIS.ca. He co-wrote four HIV national publications at CATIE, has served on the Community Advisory Committee for the Canadian Institutes of Health Research Canadian HIV Trials Network, HIV Research Ethics Board at the University of Toronto, as well as on the boards of the Alliance for South Asian AIDS Prevention and CTAC. Devan is a South Asian gay man who has been living with HIV for 34 years.
Paula Orecklin, a disability advocate who shares her experiences living with a disability with youth as a Rick Hansen Foundation Ambassador. She is also a patient and family advisor with the Winnipeg Regional Health Authority. Paula lives with chronic pain and is involved in the DAWN‒DisAbled Women's Network and the Manitoba League of Persons with Disabilities.
Marney Paradis, the Executive Director of Habitat for Humanity Yukon and a Doctor of Education candidate at the University of British Columbia, where her philosophical inquiry focuses on the intersection of anti-oppressive, community-based, and spiritual support systems within frameworks of health advocacy. Marney has a son who lives with type 1 diabetes and she is the President of Yukon T1D Support Network — a non-profit group she helped found to provide education, advocacy, and support to people in Yukon with type 1 diabetes.
Zal Press, the executive director of Patient Commando, an organization dedicated to lifting the veil of silence that so often accompanies the onset of illness. He was the founding co-Chair of The Beryl Institute Global Patient and Family Advisory Board, which works to ensure that the voices of patients and families are a central consideration in the strategic direction and offerings of the Institute. Zal has lived with Crohn disease for more than 38 years. He is passionate about illustrating the need for improved health care policy and delivery by sharing stories that enrich our appreciation of the lived illness experience.
Mary Reeves, a retired education administrator and mediator, and an active volunteer in her community. She is a founding member of the Grand Bay-Westfield Age Friendly Communities Committee, and a past Board member of the Sophia Recovery Centre — a support centre for women recovering from addictions. Mary lives with osteoarthritis and vision impairment, and is aware of the challenges of staying independent as she and her husband age.
Sarah Sandusky, a fundraising and communications specialist with extensive experience working with non-profit organizations focused on homelessness, addiction, mental illness, health, education, and human rights. She previously held leadership roles with the Dr. Peter AIDS Foundation in Vancouver, BC Civil Liberties Association, Street League in the UK, and Eva's Initiatives for Homeless Youth in Toronto. Sarah is now a freelance facilitator and fundraising strategist based in British Columbia. She is a Board member of Pain BC and has experienced the impact of chronic pain both personally and professionally.
Engaging with Canadian patients and communities is a strategic priority for CADTH. CADTH offers many opportunities for patients and their families, caregivers, advocacy groups, and communities to read, contribute to, and shape its work. Information about these opportunities is available on the CADTH Patient and Community Engagement Web pages.
About CADTH CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.
SOURCE Canadian Agency for Drugs and Technologies in Health (CADTH)
New partnership to advance medical isotope production to treat prostate cancer at Bruce Power
ETOBICOKE, ON, July 10, 2019 /CNW/ - Bruce Power is joining forces with Kinectrics and Framatome to advance an innovative project to enable the production of a key medical isotope used to treat prostate cancer known as Lutetium-177.
"This is a very exciting day as we mark the beginning of a new partnership that sets the groundwork for the production of an isotope that treats prostate cancer," said Mike Rencheck, Bruce Power's President and CEO. "We want to ensure Canada remains at the forefront of global isotope development and production. Today's announcement is a big step forward."
Innovation in targeted cancer therapies is creating a significant worldwide demand for life-saving isotopes like Lutetium-177. Utilizing the reactors at Bruce Power will help to ensure that this key medical isotope will be delivered to patients in Canada and around the world, reliably and affordably.
The partnership will focus on achieving production in 2022 following regulatory and other approvals. Bruce Power will also be working with all levels of government to progress a number of strategic export and business development opportunities connected with this project to align with several key public policy areas.
The partnership will seek to leverage the multi-unit Bruce site to provide a stable, redundant supply of Lutetium-177 for many decades to come. Kinectrics and Framatome Canada Ltd. have teamed up to develop an Isotope Production System deployable on all Bruce Power units that can also support the future production of other isotopes in addition to Lutetium-177.
"This partnership is a very important and exciting opportunity for Kinectrics," said David Harris, Kinectrics' President and CEO. "We are looking forward to working with our partners, Bruce Power and Framatome, to produce new life-saving medicine. This business venture will create many new opportunities for our companies, jobs across the province, and high-tech export sales for Canada."
This new partnership, in conjunction with Bruce Power's Life Extension program, helps to create a framework for isotope production until 2064, which is the expected life of the Bruce Power site following its Life Extension Program launched in 2016 which remains on time and on budget.
"Framatome is proud to join forces with Bruce Power and Kinectrics to produce and deliver medical isotopes that treat cancer, and further supports Canada's leadership in isotope development," said Bernard Fontana, CEO of Framatome. "This agreement builds on our long-lasting commitment to Bruce Power, and we are pleased to mobilize our world-wide expertise for advancements in the medical sector."
Christine Hogarth, MPP for Etobicoke-Lakeshore, praised the new partnership as an example of Ontario-based businesses achieving success through innovation.
"This exciting partnership exemplifies Ontario's Open for Business mantra, while contributing to an integrated system of care for cancer patients in Ontario and around the world," said Hogarth. "Leveraging existing infrastructure and expertise in Ontario, and right here in Etobicoke, will help keep hospitals clean and safe while expanding Ontario's leadership role in the global community by supporting new and innovative patient treatments."
Lutetium-177 is used in Targeted Radionuclide Therapy to treat cancers like neuroendocrine tumours and prostate cancer. Medical-grade Lutetium is used to destroy cancer cells while leaving healthy cells unaffected. Bruce Power is also a significant source of Cobalt-60 used for the sterilization of medical equipment around the world as well as a specialized form of cancer treatment called the Gamma Knife.
"An average of 11 men die from prostate cancer every day. We're working with our partners to change that statistic, developing innovative radioisotope treatments," says Peter Coleridge, President and CEO, Prostate Cancer Canada. "Radioisotopes play a crucial role from diagnosis to treating advanced forms of the disease for which there is no cure. That's why we're excited about new treatments in the pipeline that are giving men and their families hope for the future. Together, we can save and improve more lives."
Bruce Power is a founding member of the Canadian Nuclear Isotope Council (CNIC), which will ensure Canada remains a world leader in the production of life-saving radioisotopes by raising awareness and supporting long-term policies at the domestic and international level. Over 30 leading organizations from Canada and around the world have joined the council, which will develop collective solutions to maintain Canada's leadership position on the global isotope stage.
"Canadian researchers and radioisotope producers are working together to deliver innovative new therapies to clinics, and Canada's supply of these critical isotopes is important to new clinical trials and to increasing approved therapies," said James Maloney, MP for Etobicoke-Lakeshore. "Together all three companies will help to ensure Canada is a leading force in global science, while generating tremendous economic and societal benefits for all Canadians."
How it works:
An Isotope Production System on a Bruce Power unit can be used to turn targets into medical isotopes through a process referred to as irradiation. This is a similar process utilized by Bruce Power in the production of Cobalt-60.
Lutetium-177 is made by irradiating a stable isotope, Ytterbium-176.
The Ytterbium-176 is sealed in special containers and placed in the reactor for about two weeks and then it is sent for processing and distribution to health care facilities.
Each container may contain enough Lutetium-177 isotope for about 200 patient treatments.
The production of Lutetium-177 does not generate any nuclear waste as all the materials are either used for treatment of patients or are recycled to be used to produce more of the isotope.
About Bruce Power Formed in 2001, Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,200 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province. Bruce Power has worked hard to build strong roots in Ontario and is committed to protecting the environment and supporting the communities in which we live. Learn more at www.brucepower.com and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.
About Kinectrics Kinectrics is the category leader in providing life cycle management services for the electricity industry. Trusted by clients worldwide, our expertise in engineering, testing, inspection, and certification is backed by our independent laboratory and testing facilities, a diverse fleet of field inspection equipment and an award-winning team of over 1,000 engineers and technical experts. From initial design and type testing to operational deployment and maintenance services, Kinectrics collaborates closely with customers to ensure that utility assets perform safely, reliably and efficiently throughout their entire life cycle. Learn more at www.kinectrics.com and follow us on LinkedIn, Twitter, and YouTube.
About Framatome Framatome is a major international player in the nuclear energy market recognized for its innovative solutions and value-added technologies for designing, building, maintaining, and advancing the global nuclear fleet. The company designs, manufactures and installs components, fuel and instrumentation and control systems for nuclear power plants and offers a full range of reactor services. With 14,000 employees worldwide, every day Framatome's expertise helps its customers improve the safety and performance of their nuclear plants and achieve their economic and societal goals. Join the energy conversation with Framatome on Twitter: @Framatome, Facebook: @FramatomeUS and LinkedIn: @Framatome.
SOURCE Bruce Power
Keep it keto-friendly this summer with these four simple barbecue tips
With the sunshine and hot weather finally upon us, there are endless reasons to celebrate the season with family and friends. Whether it be a BBQ, patio or picnic, summer is all about eating al fresco and embracing the warmth before it’s gone.
Image Source: Unsplash The keto way of life continues to gain popularity, with social media rife with followers sharing how they’re keeping healthy and fueling their bodies this season. Concerned about carb-filled barbecues throwing a wrench into your health plans? Here are four simple tips to keep you on track and satisfied while dining out with friends and family this season.
Buns out
You don’t have to miss out on the deliciousness of a burger, chicken breast or sausage hot off a sizzling grill. Try eating your protein “naked” or with a lettuce wrap (bibb, sesame or romaine work very well!) to keep it nutritious while satisfying your barbecue craving.
Condiment conditions
Many condiments are full of hidden sugars. If you want to keep it saucy, find some new and exciting low or no sugar condiments, or stick to classics like mayonnaise, mustard and hot sauce.
Veggie forward
Summer brings the best vegetable options to your local farmers market and produce sections. Take advantage of what’s in season and fill up on your favourite leafy greens and colourful peppers to keep you feeling fresh. BBQ portobellos anyone?
Don't desert dessert
You can still satisfy your craving for dessert by swapping out a sugary last course with something that’s sweet and savoury. We recommend trying Atkins Crispy Lemon Flavour Snack Bar or the Chocolaty Peanut Butter Pretzel Bar. Containing between 160 and 200 Calories, with 1 gram of sugar and 3 grams of Net Atkins Count™ per bar, they make the perfect treat to cap off your barbecue fiesta.
Summer doesn’t have to mean taking a hiatus on your health routine and fitness goals. With so many nourishing ways to indulge, you can focus on enjoying your company and perhaps perfecting your burger flip.
About Atkins Nutritionals, Inc. Atkins Nutritionals, Inc. is a growing developer, marketer and seller of Atkins® branded nutritional food and snacking products. Its highly-focused product portfolio consists primarily of protein bars, ready-to-drink shakes, snacks and confectionery products. Over the past 45 years, the Atkins brand has become an iconic brand rooted in the nutritional principles of reduced sugar and a mindful approach to carbohydrates, with a focus on protein and good fats. Atkins products are available online at Atkins.ca and are distributed widely within Canada, the U.S. as well as Internationally. To learn more about Atkins, visit www.atkins.ca
ARE YOU MAKING THESE COMMON MISTAKES AFTER A BAD SUNBURN?
Dermatologist Says Don’t Fry Yourself With The Wrong After Sun Care
Unless you have been living under a rock, you know the importance of SPF and re-applying it.
There are times when, despite your best efforts, you still manage to get burned. Perhaps you were careless, and after too many margaritas forgot to re-apply your sunblock. Now, you are literally burned by your day of fun in the sun. Before you do anything to put yourself out of your stinging, burning agony, read these tips so you know what NOT to do to soothe a sunburn. Dr. Sheel Desai Solomon is a board- certified Raleigh- Durham North Carolina Dermatologist and founder and owner of Preston Dermatology
Here is her list of things to avoid after a bad sunburn.
Wearing Cologne
Some cologne may contain ingredients that make you more prone to burning. "Oil of bergamot is especially notorious for this," explains Dr. Solomon "and can cause a severe, blistering reaction when it's on your skin and exposed to the sun." It's become rarer in the past few years since many fragrance companies started stripping the ingredient from their products. Other perfume ingredients and essential oils, like rosemary and lavender oils, can make your skin more sensitive to the rays, too, Dr. Solomon adds. To play it safe, avoid spraying any scents onto your skin before you go outside.
Medications
Taking an anti-inflammatory medication, like acetaminophen or ibuprofen, can help soothe your skin once you're sunburned. However, nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen, can also leave you more vulnerable to getting burned in the first place.
Dr. Solomon explains, "That's because certain medications contain photosensitizing agents. Those molecules will absorb the sun's UV rays and release them back into your skin, which damages and kills skin cells."
However, NSAIDs aren't the only ones that can raise your risk of getting fried. "There is a whole slew of meds out there that can leave your skin more sensitive to sun's rays," says Dr. Solomon "meaning you need to take extra precautions before spending time outdoors." Common ones include topical acne medications like benzoyl peroxide and salicylic acid, antihistamines, and antibiotics. Even OTC supplements like St. John's Wort can make you burn more easily. Avoiding direct sunlight after applying or taking these medications is your best bet, but if you need to head outside, Dr. Solomon suggests protecting your skin with SPF 30 sunscreen and covering up with long sleeves, hats.
Taking Hot Showers
When your skin gets a little too toasted, you may notice that it tends to feel dry as it heals. Even if you're not in physical pain, taking hot showers can strip your skin of essential oils, which can dry it out even further and make it more sensitive, explains Dr. Solomon.
"This may lead to blistering and possibly prolong the healing process." On top of that, hot water isn't going to feel great, even on a mild sunburn that didn't feel too bad to begin with. While cold showers typically feel uncomfortable, sticking to lukewarm or cool showers when you're burned will ease discomfort. The temperature should be no warmer than what you would expect from a heated pool, which is around 84 degrees.
Wearing Tight Clothing
Wearing tight clothing over sunburnt skin is not advised, because inflammation is setting in. "Your body is trying to respond to the trauma by increasing blood flow to the area to help with healing. This results in redness, warmth, and inflammation to the area," says Dr. Solomon. Wearing tight clothes could amplify the response, which could lead to more intense swelling and blisters. Alternatively, you can avoid sunburns altogether and use the best sunscreen for your skin type.
Don't Use Scented Aloe
Aloe has anti-inflammatory properties and is suitable for your skin after you get a sunburn. However, using a scented aloe can irritate the skin even more. Dr. Solomon suggests using a fragrance-free aloe or using aloe directly from an aloe plant. However, the most beneficial treatment of all is to avoid sunburn in the first place.
Don't Cover that Burn With Makeup
Even though your sunburn might look bad, avoid covering it up with makeup. "The only way the burn will heal is if you let your skin breathe," says Dr. Solomon. "Introducing various makeups through dirty sponges or brushes will only increase your risk for infection or allergic reaction, which will ultimately make it all worse."
Don't Pop Your Blisters
Similar to not peeling your skin, you should never pop blisters. "That extra bubble of skin serves a fundamental purpose in protecting the wound," says Dr. Solomon. "If a blister hurts severely, apply a cream-based unscented aloe vera."
Not Drinking Enough Water
Sunburns dehydrate you from the inside out, so you really should be drinking 8 to 10 glasses of water a day to rejuvenate the skin.
Exfoliating
While scrubbing dead skin off your body helps to you then the skin, it's one of the worst things you can do on a sunburn. When your skin is burnt from the sun, exfoliating only exposes the damaged layer of skin, even more, causing pain and further irritation, explains Dr. Solomon. Instead, use a gentle moisturizer or mask to treat damaged skin.
Don't Use Coconut Oil or Butter
You may have heard before that lathering butter or coconut oil will soothe your burn, but it's a myth. The skin is hot and needs to cool down, applying a fat-based product onto your skin will not only clog the pores and stop the healing process, but it might also aggravate inflammation. "Coconut oil and butter are great for moisturizing the skin in other instances," says. Dr. Solomon, "but when it comes to a burn, you should wait until the skin cools to use it.".
Dr. Sheel Desai Solomon is a Board-Certified Raleigh-Durham, NC Dermatologist with specialty Fellowship training in Dermatopathology, Cosmetic and Laser Surgery.
Prior to founding her own practice, she served as Assistant Professor in the Department of Dermatology at Duke University Hospital.
She completed her Residency training at the renowned Ronald O. Perelman Department of Dermatology at NYU (New York), and has trained at some of the most prestigious institutions in the world, including the Ackerman Academy of Dermatopathology (New York), The Laser and Skin Surgery Center (New York), St. John's Institute of Dermatology (London, UK). She obtained her undergraduate and medical degrees at King’s College London, University of London.
She is a member of The American Board of Dermatology, The American Academy of Dermatology, The North Carolina Dermatology Association, The American Society for Dermatologic Surgery, and The American Society For Laser Medicine & Surgery.
Born and raised in the United Kingdom, she brings a global perspective to patient care. She is also conversant in several languages including French, German and Japanese.
Medicine is a common thread in Dr. Desai Solomon’s family with many of her family members being physicians and surgeons. Her grandmother Lalita was one of the first women doctors to graduate and practice in India and a noted philanthropist.
Dr. Desai Solomon is excited to use her skills, experience, research and the latest cutting-edge technology to help patients achieve optimal skin health and realize their aesthetic goals.
When not running her busy practice, Dr. Desai Solomon is a wife and a mother of two young children. In her spare time she enjoys keeping active, cooking, charity work and the fine arts.
She believes that body and mind wellness has a huge impact on our skin and encourages a holistic approach with patients.
Canfitpro 2019 will make you sweat on August 16 & 17
TORONTO, July 11, 2019 /CNW/ - Come workout and sweat at Canada's largest fitness event, canfitpro 2019. The canfitpro 2019 trade show will be take place on Friday August 16 and Saturday August 17 with this year's admission being completely free. Trade show passes are available in advance at http://www.canfitpro2019.com.
As Canada's leader in fitness education, more speakers from the fitness industry around the world have been added to the trade show this year. canfitpro 2019 trade show now has a larger, more diverse agenda with over 65 inspiring sessions featuring prominent leaders and speakers; our new experiential trade show zones highlight Group Fitness, Health & Nutrition, Power & Performance and Technology & Innovation.
Some of these educational session highlights include:
FRIDAY AUGUST 16 "Happiness and Exercise" – Dr. Gillian Mandich "Sugar and Mood: Understanding How Sugar Impacts Your Mood & Energy" – Tosca Reno "Joga HIIT: A Program that Bridges the Gap Between Yoga & Sport" – Jana Webb
SATURDAY AUGUST 17 "Longevity Hack – How to Increase Health Span and Improve with Age" – Dr. Marc Bubbs "Regular to Ripped: HIIT the New Fat Burning Zone" – Mike Bracko "Setback to Comeback: The Rise and Fall of the Middle-Aged Athlete" – Fraser Quelch
In Hall D Activity Stage, throughout the two days, come build up a sweat with STRONG by Zumba®, POUND® - Rockout. Workout with the legendary Tae Bo®creator Billy Blanks.
On Saturday August 17, experience the 2019 GNC ALLMAX canfitpro Natural Regional Championships starting at 10am on the Hall E Power & Performance Stage.
OTHER HIGHLIGHTS WITHIN THE CANFITPRO 2019 TRADE SHOW:
As part of connecting the fitness industry to professionals and enthusiasts, this year's trade show will include appearances by:
Billy Blanks – creator of Tae Bo® Ashley Callingbull - Actor, Beauty Queen, First Nations Activist Jenalyn Saraza Pacheco and Luka Milacic Perusina - "World of Dance" contestants
The canfitpro 2019 trade show takes place at the Metro Toronto Convention Centre Friday August 16 (11:30am to 7pm) and Saturday August 17 (9am to 5:30pm).
canfitpro is the largest provider of education in the Canadian fitness industry. Founded in 1993, canfitpro delivers accessible, quality education, certifications, conferences, trade shows, and membership services. canfitpro's over 24,000 members include some of the world's finest fitness professionals, health club operators, industry suppliers, and fitness consumers.
SOURCE canfitpro
Raymond James Strengthens Healthcare, Biotechnology, and Cannabis Research: Rahul Sarugaser Joins Canadian Team
TORONTO, July 11, 2019 /CNW/ - Raymond James Ltd., the Canadian arm of North American investment dealer Raymond James Financial Inc., today announced that Rahul Sarugaser has joined its Canadian Equity Research team as Managing Director, Equity Analyst, Healthcare, Biotechnology & Cannabis.
"Rahul brings a combination of extensive medical sector expertise and financial analysis into this important role," says Daryl Swetlishoff, Head of Research at Raymond James Ltd. "Our focus will be on covering Canadian growth-oriented firms pursuing enhanced medical solutions in the biotechnology, healthcare, wellness, medical devices, and cannabis fields."
Rahul holds a PhD and MASc in Biomedical Engineering from the University of Toronto, and an MBA from the University of Oxford.
Also joining Rahul is Michael Freeman, Equity Research Associate. Michael has solid engineering and biotechnology industry experience and holds an MASc in Chemical Engineering from the University of Toronto.
Raymond James is strongly positioned in the Healthcare sector across North America, with a team of 45 dedicated Healthcare investment bankers and 15 research analysts covering over 260 Healthcare companies. "With changing technologies and ground breaking scientific discoveries, the Healthcare industry is evolving rapidly," says Rahul Sarugaser. "Partnering with Raymond James' powerful Healthcare team creates an exciting opportunity to uncover differentiated investment ideas for our Institutional and Private Client investors alike."
Raymond James is a leading North American independent full service investment dealer offering an extensive range of professional investment services and products, including: private client services, financial and estate planning services, portfolio management, insurance, equity research, investment banking, and institutional sales and trading. Through its network of approximately 7,900 financial/investment advisors across Canada, the United States, and key international centres, Raymond James manages more than US$796 billion in client assets under administration. The firm also has over 65 research analysts covering more than 1,300 companies in Canada, the United States, and internationally.
SOURCE Raymond James Ltd.
ESPEROCT® is now approved in Canada for the Treatment of Hemophilia A in both Children and Adults
New treatment can help Canadians living with hemophilia A better manage their bleeding episodes
TORONTO, July 12, 2019 /CNW/ - Novo Nordisk announced today that Health Canada has approved ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) for use in adults and children with hemophilia A (congenital Factor VIII deficiency) for:
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
On-demand treatment and control of bleeding episodes
Perioperative management of bleeding.1
"Canadians living with hemophilia A are at risk of bleeding for longer periods of time. If not treated appropriately, those bleeding episodes, particularly into joints and muscles, can be painful, lead to joint damage and muscular atrophy over the patient's lifetime and in some cases can be life threatening," said Dr. Anthony Chan, OOnt, Professor of Paediatrics, McMaster University. "ESPEROCT® has been shown to be effective in reducing the risk of bleeding episodes among patients."
Health Canada's approval is based on the findings from three multinational, open-label, non-controlled trials in male subjects with severe hemophilia A, which is defined as having less than 1 per cent of the normal level of factor VIII in the blood.2,3 All subjects were previously treated, having received other FVIII products for more than 150 exposure days for adolescents and adults and more than 50 exposure days for pediatric subjects.4
"The Canadian Hemophilia Society advocates for access to the widest possible range of coagulation therapies and welcomes the regulatory approval of this additional option for the treatment of hemophilia A," said Paul Wilton, President, Board of Directors, Canadian Hemophilia Society.
Overall, ESPEROCT® was shown to provide effective prophylaxis and maintain a low median ABR of 1.18 when dosed at 50 IU/kg every 3-4 days in adults and adolescents (those aged 12 years and over) and a median ABR of 1.95 in children under 12 years of age when dosed twice weekly at 60 IU/kg (50-75 IU/kg).5
Across the clinical trials and age groups, ESPEROCT® was well tolerated and had no safety concerns identified.6 The safety profile of ESPEROCT® is similar to what has been reported for other long-action FVIII products.7
About Hemophilia A
Hemophilia A is an X-linked, recessive disorder caused by a deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation.8 One out of three cases for the estimated 2,500 Canadians living with hemophilia A are caused by a new genetic mutation. 9,10 The most common symptom associated with hemophilia is a bleeding problem, which can lower the overall quality of life for many patients.11
About ESPEROCT®
ESPEROCT® (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A. In adults, the half-life for ESPEROCT® was determined to be 19 hours compared to 12 hours for unmodified FVIII products, using the chromogenic assay.12
About Novo Nordisk
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries, and markets its products in more than 170 countries. For more information, visit novonordisk.ca, Twitter and YouTube.
CAN YOU BIOHACK YOUR BRAIN FOR A BETTER RELATIONSHIP?
Neuroscience Expert Shares Fascinating Link Between Brainwave Training & Its Effect on Romance & Emotional HealthDating and relationships are hard work - especially in 2019. The changing face of modern romance has led to some pretty depressing stats: A recent survey found that more than 50% of sexually active individuals are dissatisfied with their sex lives; only 30% of Internet daters are in search of true love as opposed to hookups; and a staggering 23% of women aren’t happy in their relationships! It's no wonder nearly half of all marriages today end in divorce.Before you lose all faith in modern romance and turn your back on love, there may be some hope. Though some argue technology is the leading culprit in romantic demise, new tech has also given us incredible insight into love and relationships. According to Neuroscience expert Dr. Patrick Porter, there is a fascinating link between brainwaves and romance.We can't see it, but brains hum with these waves of electrical activity. At the root of all our thoughts, emotions, and behaviors is the communication between neurons within our brains. Changing our brainwaves has a dramatic effect on our physical, mental, and emotional health."Brainwave training has been found to help people de-stress and achieve emotional balance. It is proven to help people who struggle with stress, anxiety, difficulty sleeping, fatigue, - all of which are extremely important factors when it comes to romance and relationships..."...says Dr. Porter, who recently presented research along with Arianna Huffington at the National Biohacking Conference in Los Angeles. According to research, sleep plays a major role in relationships. When we sleep poorly, the parts of our brain devoted to emotional empathy don’t function as well. Sleep loss causes social withdrawal and loneliness and it helps us to be less angry and aggressive. Not surprisingly, anxiety and stress can also negatively impact your relationship. It can lead to inappropriate suspiciousness or paranoia, overthinking, being indecisive, and an appropriate need for reassurance and support.Though there are several methods of brainwave entrainment, one of the most effective is "braintapping" which uses auditory and visual stimulation to synchronize and balance brainwaves. As the light and sound frequency changes, so does the frequency in the brain. Brainwave training stabilizes the limbic system which is involved in motivation, emotion, learning, and memory. Your body is calmed, your breathing becomes rhythmic, your hands warm, and your muscles relax. "The light and sound stimulation boost brain levels of serotonin, beta-endorphins, and norepinephrine. These are the same chemicals that are released during attraction and make us giddy, energetic, and euphoric," says Porter. Brainwave training and biohacking have made tremendous advances in treating mental health conditions which are closely tied to relationships. Although in the past, brainwave training and biohacking have received criticism for being unregulated, biohackers argue that's exactly why it needs to be studied and have close attention by the public. Dr. Porter is sharing the fascinating link between brainwave training and its impact on romance and emotional health and he can also explain why balancing brainwaves may improve your love life.IN AN INTERVIEW OR ARTICLE, DR. PORTER CAN DISCUSS:Brainwaves and relationships: the science of love.The fascinating link between brainwave training and its impact on romance and emotional health.Why balancing brainwaves may improve your love life.Biohacking - the latest trend in health and wellness.How to biohack your brain with light, sound, and vibration.What mainstream biohacking means for the healthcare industry. ABOUT DR. PATRICK PORTER:Dr. Patrick K. Porter, PhD, is an award-winning author and speaker who has devoted his career to neuroscience and brainwave entrainment. As the creator of BrainTap Technology™, Porter has emerged as a leader in the digital health and wellness field. BrainTap’s digital tools and mind development apps use Creative Visualization and Relaxation, a biohacking technique that has made tremendous advances in treating mental, physical, and emotional health issues. Braintap has been praised for helping people overcome stress and insomnia, lose weight, stop smoking, manage pain, accelerate learning, and much more. FOR MORE INFORMATION, VISIT: www.braintap.com
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
